Stocks
Amylyx Pharmaceuticals (AMLX) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 16 287% | 12 476% | 3 700% | 10 329% | 23 650% | ||||
| Changes by years, y/y, % | -3 811pp | -8 776pp | +6 630pp | -14.1% | |||||
Amylyx Pharmaceuticals. R&D/CAPEX, %
Amylyx Pharmaceuticals. R&D/CAPEX, changes, pp
Amylyx Pharmaceuticals (AMLX) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 8 414% | 12 616% | 54 169% | 25 999% | 111 774% | 23 650% | ||
| Changes by years, y/y, % | +2 986pp | +8 937pp | +44 492pp | +15 551pp | +103 360pp | |||
| Changes by quarters, q/q, % | -2 034pp | +4 203pp | +41 552pp | -28 170pp | +85 775pp | |||
